GlassScriptPhysician profile
Michael L Margolin
NPI 1053316653
$4,929.99
in general payments reported to CMS, 2019-2025
25 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $312 · 2021: $633 · 2022: $927 · 2023: $909 · 2024: $632 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,710.58 | 2019-2025 | |
| Pfizer INC. | $728.52 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $491.43 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.25 | 2019-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $403.21 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $308.93 | 2019-2025 | Tremfya, Stelara, Remicade |
| Qol Medical, LLC | $198.50 | 2021-2025 | Sucraid |
| Lilly USA, LLC | $103.73 | 2023-2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $90.52 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $84.34 | 2021-2023 | |
| Celltrion USA INC. | $62.80 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $55.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $52.10 | 2021-2024 | Suflave |
| Aimmune Therapeutics, INC. | $43.56 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $29.34 | 2025 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.61 | 2019 | |
| Novo Nordisk INC | $18.99 | 2025 | Wegovy |
| Genzyme Corporation | $15.71 | 2022 | |
| Sandoz INC. | $15.48 | 2024 | Hyrimoz |
| Exact Sciences Corporation | $14.87 | 2025 | The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $14.67 | 2022 | |
| Olympus America INC. | $14.16 | 2021 | |
| Merck Sharp & Dohme LLC | $13.80 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.26 | 2019 | |
| Ferring Pharmaceuticals INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Margolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.